Aoki T, Kudo M, Nishida N, Ueshima K, et al. Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study. J Gastroenterol 2025 Mar 7. doi: 10.1007/s00535-025-02233.
PMID: 40055288